

Performance in Delivering Research (PID) Q2 2017-18

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number of Study Participants Recruited	Reason For Closure Of Trial	Comments
11/NW/0246	75784	STAR: A randomised multiStage phase II/III trial of Standard first-line therapy (sunitinib or pazopanib) comparing Temporary cessation with Allowing continuation, in the firstline treatment of locally advanced and/or metastatic Renal cancer	Number Agreed	10	31/05/2017	40	31/07/2017	40	Recruitment Finished	
13/LO/0822	108709	VinCaP - A phase II trial of Vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis	Number Agreed	2	31/03/2017	2	14/07/2017	2	Recruitment Finished	
16/LO/0919	201803	A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4Antibody) in Subjects with Advanced Solid Tumors	Number Agreed	6	31/12/2017	1	17/07/2017	1	Withdrawn By Host	PI left the Trust in April 2017 and was agreed to close to recruitment
16/NW/0379	200426	Protocol I3O-MC-JSBF Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Gemcitabine and Cisplatin as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer	Number Agreed	4	25/04/2018	0	28/07/2017	0	Withdrawn By Sponsor	Study closed early by sponsor - sample size reached